

This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Musculoskeletal disease				
Bone repair	Histone deacetylase (HDAC)	<p>Cell culture and animal studies suggest that largazole could help stimulate bone formation to treat bone disorders. In a cellular model of osteogenesis, the cyclic depsipeptide-based HDAC inhibitor largazole increased osteoblast differentiation compared with no treatment. In a mouse bone formation assay, collagen implants containing largazole increased bone formation compared with vehicle. In a rabbit bone fracture model, implanted calcium phosphate scaffolds containing largazole increased bone regeneration compared with implanted scaffold alone. Next steps could include testing largazole in additional animal models of bone repair.</p> <p>SciBX 4(9); doi:10.1038/scibx.2011.259 Published online March 3, 2011</p>	Patent and licensing status unavailable	<p>Lee, S.-U. <i>et al. ACS Med. Chem. Lett.</i>; published online Jan. 4, 2011; doi.10.1021/ml1002794</p> <p>Contact: Seong Hwan Kim, Korea Research Institute of Chemical Technology, Daejeon, South Korea e-mail: hwan@kRICT.re.kr</p> <p>Contact: Jiyong Hong, Duke University, Durham, N.C. e-mail: jiyong.hong@duke.edu</p>